IBLHL stock snapshot.
IBL HealthCare Limited price, fundamentals, financial report trends, and one-year performance against the KSE-100.
IBLHL vs. KSE-100
Latest report-period signals.
Parsed conservatively from PSX financial report PDFs. Card values are latest report-period figures, so quarterly filings show quarterly values rather than annualized totals.
Report metrics extracted
| Stock | Trailing P/E | Price / book | ROE | Net margin | Debt / equity | Market cap | Day change |
|---|---|---|---|---|---|---|---|
IBLHL IBL HealthCare Limited | 20.15 | 1.94 | 8.97% | 4.82% | 74.38% | PKR 4.8bn | -0.48% |
| GLAXO →GlaxoSmithKline Pakistan Limited | 10.98 | 3.03 | 29.77% | 15.21% | 48.79% | PKR 110.1bn | -0.21% |
| ABOT →Abbott Laboratories (Pakistan) Limited | 11.27 | 2.67 | 25.19% | 10.57% | 48.93% | PKR 89.8bn | +0.36% |
| HALEON →Haleon Pakistan Limited | 13.82 | 6.05 | 43.07% | 14.78% | 105.49% | PKR 88.1bn | -0.15% |
| AGP →AGP Limited | 22.65 | 3.97 | 18.27% | 11.49% | 62.09% | PKR 53.5bn | -0.20% |
IBL HealthCare Limited
IBL HealthCare Limited was incorporated in Pakistan under the repealed Companies Ordinance, 1984 (now the Companies Act, 2017) as a private limited company on July 14, 1997. In November 2008, the Company was converted into public limited company. The principal activities of the Company include marketing, selling and distribution of healthcare products.
Turn IBLHL from a quote into a decision trail.
PSX Clarity connects live prices, filings, dividends, and report metrics to the portfolio you actually follow.